Events, News, Presentations, Press Releases
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023 – Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage...
